Literature DB >> 11411816

The apparent effects of ziprasidone on plasma lipids and glucose.

S J Kingsbury1, M Fayek, D Trufasiu, J Zada, G M Simpson.   

Abstract

BACKGROUND: We examined the effects of ziprasidone on body mass index (BMI) and serum levels of glucose, cholesterol, and triglycerides.
METHOD: As part of a multicenter study examining different strategies for switching to ziprasidone from other antipsychotics, we evaluated weight and serum glucose, cholesterol, and triglyceride measurements at baseline and following 6 weeks on ziprasidone treatment in 37 patients at our site.
RESULTS: Short-term treatment with ziprasidone appeared to lead to significant reduction in serum cholesterol (p < .001) and triglyceride levels (p = .018) independent of changes in BMI. Ziprasidone treatment appeared to have no significant effect on BMI or glucose level, perhaps due to the small number of subjects.
CONCLUSION: Ziprasidone appears to independently lead to a lowering of serum lipid levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11411816     DOI: 10.4088/jcp.v62n0507

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

Review 1.  Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.

Authors:  Trino Baptista; N M K Ng Ying Kin; Serge Beaulieu
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Psychotic symptoms in patients with medical disorders.

Authors:  Ashwin A Patkar; Rajnish Mago; Prakash S Masand
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

Review 4.  Ziprasidone in the management of schizophrenia : the QT interval issue in context.

Authors:  David Taylor
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 5.  [Atypical antipsychotics and metabolic syndrome].

Authors:  Andreas Baranyi; Renè Yazdani; Alexandra Haas-Krammer; Alexandra Stepan; Hans-Peter Kapfhammer; Hans-Bernd Rothenhäusler
Journal:  Wien Med Wochenschr       Date:  2007

6.  Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.

Authors:  Gail L Daumit; Donald C Goff; Jonathan M Meyer; Vicki G Davis; Henry A Nasrallah; Joseph P McEvoy; Robert Rosenheck; Sonia M Davis; John K Hsiao; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2008-09-04       Impact factor: 4.939

7.  Increased Silent Brain Infarction Accompanied With High Prevalence of Diabetes and Dyslipidemia in Psychiatric Inpatients: A Cross-Sectional Study.

Authors:  Tetsuto Kanzaki; Yoriyasu Uju; Keisuke Sekine; Yukihiro Ishii; Taro Yoshimi; Reiko Yasui; Asuka Yasukawa; Mamoru Sato; Seiko Okamoto; Tetsuya Hisaoka; Masafumi Miura; Shun Kusanishi; Kanako Murakami; Chieko Nakano; Yasuhiko Mizuta; Seisuke Mimori; Shunichi Mishima; Kazuei Igarashi; Tsuyoshi Takizawa; Tatsuro Hayakawa; Kazumi Tsukada
Journal:  Prim Care Companion CNS Disord       Date:  2015-03-26

Review 8.  Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.

Authors:  Kristina Melkersson; Marja-Liisa Dahl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Weight gain, obesity, and psychotropic prescribing.

Authors:  Nikhil Nihalani; Thomas L Schwartz; Umar A Siddiqui; James L Megna
Journal:  J Obes       Date:  2011-01-17

10.  Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.

Authors:  Subin Park; Ki Kyoung Yi; Min-Seon Kim; Jin Pyo Hong
Journal:  Behav Brain Funct       Date:  2013-07-19       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.